Source:
HindustanDainik Bhaskar
Subject: Health, Governance and Regulation of Drugs (Public Health, Consumer Protection)|Target exams: UPPSC, UP SI
Key points for Prelims: Spurious and substandard drugs, Drugs and Cosmetics Act, 1940, Uttar Pradesh Food Safety and Drug Administration, Fake billing, Interstate drug network
Mains syllabus mapping
- General Studies Paper 2: Health sector: regulation of drugs, role of state agencies, public health
- General Studies Paper 3: Internal security: organised crime, role of police in economic and health crimes
Key facts for one-day exams
- Uttar Pradesh authorities seized spurious and suspected medicines valued at ₹7.57 crore.
- The campaign led to 24 FIRs naming 45 firms and 90 individuals.
- Agra and Lucknow each accounted for nine FIRs.
- Two illegal manufacturing units faced action in Dehradun.
- Two illegal manufacturing units faced action in Solan.
Uttar Pradesh spurious medicine crackdown: why in the news?
The Uttar Pradesh Food Safety and Drug Administration has seized ₹7.57 crore worth of spurious and suspected medicines and registered 24 FIRs against an interstate fake-drug network, revealing the use of fake billing and multiple licences across four states.
The Uttar Pradesh Food Safety and Drug Administration has seized spurious and suspected medicines worth ₹7.57 crore in a crackdown on an interstate fake-drug network, officials said. The campaign has resulted in 24 first information reports naming 45 firms and 90 individuals across seven districts. Investigators found that the network used fake billing, multiple drug licences and separate firms operating under the same name to manufacture, store and sell counterfeit versions of popular branded medicines.
In the Amroha-Moradabad area, eight drug-firm licences were obtained under the same name and partnership, with alleged fake billing used instead of genuine counter-to-counter sales; police arrested three accused in that case. District-wise, Agra and Lucknow accounted for nine FIRs each, Varanasi had two, and Saharanpur, Gonda, Meerut and Raebareli had one each. Action against illegal manufacturing units covered six locations across four states: one at Deoband in Saharanpur, two in Dehradun, one in Ujjain and two in Solan.
Uttar Pradesh Food Safety and Drug Administration Secretary and Commissioner Dr Roshan Jacob said the trade in spurious medicines is an attack on patients' health and life and will not be tolerated. The department's objective, he said, is not limited to seizures and arrests but extends to dismantling the entire network from the manufacturing source to the final link in the supply chain.
What law governs spurious drugs in India?
The Drugs and Cosmetics Act, 1940, is the primary legislation regulating the manufacture, sale and distribution of drugs in India. The Act defines 'spurious drugs' under Section 17-B and prescribes penalties for their manufacture and sale under Section 27. The Act was amended in 2008 to strengthen the regulatory framework and enhance penalties for offences involving spurious and adulterated drugs. The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India, works with state drug controllers to enforce these provisions.
How did the network operate?
Investigators found that the alleged network used fake billing, multiple drug licences and separate firms operating under the same name to manufacture, store and sell counterfeit versions of popular branded medicines. In the Amroha-Moradabad case, eight drug-firm licences were obtained under the same name and partnership, with fake billing used instead of genuine counter-to-counter sales. Police arrested three accused in that case.
What is the interstate dimension?
Action against illegal manufacturing units covered six locations across four states: one at Deoband in Saharanpur (Uttar Pradesh), two in Dehradun (Uttarakhand), one in Ujjain (Madhya Pradesh) and two in Solan (Himachal Pradesh). The department is now investigating suppliers, firms and other links connected to these units.
What is the stated enforcement objective?
Uttar Pradesh Food Safety and Drug Administration Secretary and Commissioner Dr Roshan Jacob said the department's objective is not limited to seizures and arrests but extends to dismantling the entire network from the manufacturing source to the final link in the supply chain. The campaign aims to trace the chain from illegal manufacturing sources to suppliers.
Uttar Pradesh connection
Key terms
- First information report:
- A first information report is the information recorded by police about the commission of a cognizable offence.
- Drug supply chain:
- The drug supply chain comprises the stages through which medicines move from manufacture to distribution and sale.
- Counterfeit medicine:
- A counterfeit medicine is a product falsely presented as an authentic medicine, including through imitation branding or packaging.
Uttar Pradesh spurious medicine crackdown: why it matters for exams
Exams: UPPSC, UP SI
Syllabus: Governance: Public health regulation and enforcement; Society: Public health and patient safety
Common mistake: Examiners may present the entire ₹7.57 crore seizure as confirmed counterfeit medicines; the stated seizure includes both spurious and suspected medicines.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Spurious medicines seized in an interstate network in Uttar Pradesh point to systemic weaknesses in drug regulation. Critically examine the regulatory gaps that allow counterfeit drugs to reach patients and suggest measures to strengthen the drug supply chain.
Answer outline
- Introduction: Open by noting that the UP crackdown, with ₹7.57 crore of seized medicines and 24 FIRs against 45 firms and 90 individuals, shows that counterfeit medicines are an organised, multi-state business that threatens patient life.
- Body:
- Regulatory gaps exposed: multiple drug licences obtained under the same name, fake billing that bypassed genuine sales records, and separate firms operating under one identity across four states.
- Enforcement challenge: manufacturing units located in several states (Deoband, Dehradun, Ujjain, Solan) make jurisdiction and coordination between state drug regulators difficult.
- Supply-chain vulnerability: counterfeits enter at manufacturing, storage and retail levels, so inspection must cover the whole chain, not only final sale points.
- Capacity and governance issues: shortage of inspectors, weak licence verification and the need for digital traceability such as track-and-trace systems.
- Way forward: stronger inter-state coordination under the Drugs and Cosmetics Act, 1940, mandatory digital licensing checks, penalties deterrent enough to end the trade, and better public awareness.
- Conclusion: Counterfeit drugs can be curbed only through a combination of tighter licensing, interstate cooperation and end-to-end supply-chain surveillance, treating drug safety as a public health priority.
Question 2(GS-3 | 150 words | 10 marks)
Organised crime in the drug trade blurs the line between economic offences and threats to public health. Discuss the role of police and state regulatory agencies in tackling such networks and the challenges they face.
Answer outline
- Introduction: Link the case to the way the Uttar Pradesh police and the Food Safety and Drug Administration jointly arrested accused persons and dismantled a network that spans states.
- Body:
- Role of police: investigation, arrests (three accused in the Amroha-Moradabad case), and tracing of linked firms across districts.
- Role of regulators: licence verification, inspection of manufacturing units, and seizure of stock worth ₹7.57 crore.
- Challenges: interstate jurisdiction, fake or overlapping firm identities, and the need for specialised forensic and financial investigation.
- Need for a whole-of-government approach: data sharing and coordinated action from source to supply chain.
- Conclusion: Effective action against drug networks needs integrated policing and regulation, backed by inter-state coordination and sustained capacity building.
Stuck? Get it in one tap
Uttar Pradesh authorities are investigating a network allegedly selling medicines using copied brand packaging and false bills. Spurious medicines are falsely presented as genuine products, while suspected medicines require investigation. Authorities are tracing manufacturers and suppliers across states.
- Governance: Public health regulation and enforcement
- Society: Public health and patient safety
Related concepts: First information report, Drug supply chain, Counterfeit medicine
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which state is Deoband, where an illegal medicine manufacturing unit faced action, located in?
Explanation: Deoband is in Saharanpur district of Uttar Pradesh. Dehradun, Ujjain and Solan are in Uttarakhand, Madhya Pradesh and Himachal Pradesh respectively.
- Q2Medium
What was the stated value of spurious and suspected medicines seized in the Uttar Pradesh campaign?
Explanation: The campaign's cumulative seizure was valued at ₹7.57 crore. The other figures do not match that value.
- Q3Medium
Why is the Uttar Pradesh Food Safety and Drug Administration tracing suppliers and manufacturing sources in the spurious-medicine investigation?
Explanation: The enforcement objective is to trace the network from manufacturing sources to the final supply-chain link. Identifying licensing violations, limiting action to one district and laboratory quality testing of seized medicines are not that objective.
Frequently asked questions
1. How many FIRs were registered in the Uttar Pradesh spurious-medicine campaign?
A total of 24 FIRs were registered, naming 45 firms and 90 individuals.
2. Where were illegal medicine manufacturing units acted against?
Action covered Deoband, Dehradun, Ujjain and Solan across four states.
3. How did the Amroha-Moradabad drug network allegedly operate?
Eight drug-firm licences were obtained under the same name and partnership, with alleged fake billing used instead of genuine counter-to-counter sales.
All sources
Original20 November 2026 · Read storyMerged20 November 2026 · Read story

